Hongtao Li

Bengbu, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial.

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial.

Journal: JAMA oncology
Published: June 01, 2026

Pyrotinib Plus Trastuzumab and Docetaxel with Different Antidiarrheal Strategies in Patients with HER2-Positive Recurrent or Metastatic Breast Cancer (PHAENNA): A Multicenter, Phase 1 Trial.

Pyrotinib Plus Trastuzumab and Docetaxel with Different Antidiarrheal Strategies in Patients with HER2-Positive Recurrent or Metastatic Breast Cancer (PHAENNA): A Multicenter, Phase 1 Trial.

Journal: Cancer research and treatment
Published: April 12, 2026

Ultrasensitive on-chip biosensing of MUC1 enabled by LSPR-enhanced two-channel optofluidic lab-in-fiber platform.

Ultrasensitive on-chip biosensing of MUC1 enabled by LSPR-enhanced two-channel optofluidic lab-in-fiber platform.

Journal: Optics express
Published: November 11, 2025

F-box/WD Repeat-Containing Protein 5 Promotes Breast Cancer Progression by Regulating Ferroptosis via Enhancing Krüppel-like Factor 13 Ubiquitination Through Phosphoinositide 3-Kinase/Serine/Threonine Protein Kinase Pathway.

F-box/WD Repeat-Containing Protein 5 Promotes Breast Cancer Progression by Regulating Ferroptosis via Enhancing Krüppel-like Factor 13 Ubiquitination Through Phosphoinositide 3-Kinase/Serine/Threonine Protein Kinase Pathway.

Journal: Rejuvenation research
Published: April 14, 2025

CLEC3A Promotes Immune Evasion and Tumor Progression by Enhancing PD-L1 Stability to Weaken T Cell Cytotoxicity in Luminal Breast Cancer.

CLEC3A Promotes Immune Evasion and Tumor Progression by Enhancing PD-L1 Stability to Weaken T Cell Cytotoxicity in Luminal Breast Cancer.

Journal: Breast cancer (Dove Medical Press)
Published: April 09, 2025

RSDCNet: An efficient and lightweight deep learning model for benign and malignant pathology detection in breast cancer.

RSDCNet: An efficient and lightweight deep learning model for benign and malignant pathology detection in breast cancer.

Journal: Digital health
Published: January 24, 2025

8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trial.

8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trial.

Journal: Breast cancer research : BCR
Published: December 17, 2024

Efficacy and safety of JMT103 in patients with bone metastases from solid tumors: A randomized Phase Ib clinical trial.

Efficacy and safety of JMT103 in patients with bone metastases from solid tumors: A randomized Phase Ib clinical trial.

Journal: International journal of cancer
Published: August 27, 2024

The role of CSTF2 in cancer: from technology to clinical application.

The role of CSTF2 in cancer: from technology to clinical application.

Journal: Cell cycle (Georgetown, Tex.)
Published: January 03, 2024

Evaluation of bioequivalence and safety analysis of capecitabine tablets and Xeloda® under postprandial dosing conditions in Chinese patients with solid tumor.

Evaluation of bioequivalence and safety analysis of capecitabine tablets and Xeloda® under postprandial dosing conditions in Chinese patients with solid tumor.

Journal: Expert opinion on drug metabolism & toxicology
Published: December 07, 2023

A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx ® in advanced breast cancer.

A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx ® in advanced breast cancer.

Journal: Frontiers in oncology
Published: October 14, 2022

A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin® in healthy Chinese male subjects.

A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin® in healthy Chinese male subjects.

Journal: BMC pharmacology & toxicology
Published: September 05, 2022
Showing 1-12 of 15

Last Updated: 09/26/2026